These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15193460)

  • 1. Tools for making correct decisions regarding hormone therapy. part I: background and drugs.
    Shoham Z; Kopernik G
    Fertil Steril; 2004 Jun; 81(6):1447-57. PubMed ID: 15193460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tools for making correct decisions regarding hormone therapy. Part II. Organ response and clinical applications.
    Kopernik G; Shoham Z
    Fertil Steril; 2004 Jun; 81(6):1458-77. PubMed ID: 15193461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women.
    Shifren JL; Desindes S; McIlwain M; Doros G; Mazer NA
    Menopause; 2007; 14(6):985-94. PubMed ID: 17507833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogens and the skin.
    Brincat MP; Baron YM; Galea R
    Climacteric; 2005 Jun; 8(2):110-23. PubMed ID: 16096167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
    Chu MC; Cosper P; Nakhuda GS; Lobo RA
    Fertil Steril; 2006 Dec; 86(6):1669-75. PubMed ID: 17074346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
    Stefanick ML
    Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal natural progesterone cream for postmenopausal women: inconsistent data and complex pharmacokinetics.
    Elshafie MA; Ewies AA
    J Obstet Gynaecol; 2007 Oct; 27(7):655-9. PubMed ID: 17999287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hormone therapy on the enteroinsular axis.
    Sztefko K; Rogatko I; Milewicz T; Józef K; Tomasik PJ; Szafran Z
    Menopause; 2005; 12(5):630-638. PubMed ID: 16145319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of estrogens and progestogens: influence of different routes of administration.
    Kuhl H
    Climacteric; 2005 Aug; 8 Suppl 1():3-63. PubMed ID: 16112947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
    Sonnet E; Lacut K; Roudaut N; Mottier D; Kerlan V; Oger E
    Clin Endocrinol (Oxf); 2007 May; 66(5):626-31. PubMed ID: 17492948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of oral but not transdermal estrogen therapy with enhanced platelet reactivity in a subset of postmenopausal women.
    Flaumenhaft R; Nachtigall M; Lowenstein J; Nachtigall L; Nachtigall R; Nachtigall L
    Menopause; 2009; 16(2):407-12. PubMed ID: 18989235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation.
    Sitruk-Ware R
    Climacteric; 2007 Oct; 10(5):358-70. PubMed ID: 17852138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Estrogens and pharmacological modulation of estrogen receptors].
    Sanidize TV; Ratiani LR; Gabuniia LIu; Tortladze ML; Kuridze NN
    Georgian Med News; 2009 Feb; (167):99-102. PubMed ID: 19276483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.